00:29 , Jun 20, 2019 |  BC Innovations  |  Distillery Techniques

Clinically relevant genomic alterations in metastatic breast cancers

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Genomic analyses have identified sets of genetic alterations that could help diagnose hormone receptor (HR)-positive, HER2-negative metastatic breast cancer subtypes and predict associated prognoses. An analysis comparing...
14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
20:08 , Oct 24, 2018 |  BC Innovations  |  Translation in Brief

Common drivers in neuroendocrine tumors

A University of California Los Angeles team is taking steps towards identifying new targets that could be exploited to address treatment-resistant small cell neuroendocrine tumors, regardless of tissue of origin. In a Science paper published...
21:39 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer In vitro , cell culture and mouse studies identified a SALL4-derived peptide inhibitor of the SALL4-RBBP4 interaction that could help treat hepatocellular carcinoma (HCC). Chemical synthesis and in vitro testing of analogs...
22:50 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Retinoblastoma Mouse studies suggest inhibiting KDM5A could help treat RB1-deficient retinoblastoma. In an RB1-haploinsufficient mouse model of retinoblastoma, systemic knockout of KDM5A decreased tumor growth and increased survival compared with normal KDM5A expression. Next...
22:43 , Apr 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy CRISPR-based gene editing with an engineered Cas9-based fusion protein that enhances homology-dependent repair (HDR) could enable greater integration of therapeutic genes than standard Cas9. The system utilizes an engineered enzyme consisting of...
16:13 , Jun 7, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with vHL , p53 and RB1 knocked out could be used to help screen therapies for clear cell renal cell carcinoma (ccRCC). In mice, renal epithelial cell-specific knockout of all...
22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
00:11 , Mar 10, 2017 |  BC Innovations  |  Targets & Mechanisms

Poly drugs for polycomb

In parallel studies, Novartis AG and Abbvie Inc. have reported inhibitors of the epigenetic regulator PRC2 that block the protein by a new mechanism, offering a complement to the inhibitors in the clinic, and more...
02:10 , Feb 14, 2017 |  BioCentury  |  Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...